Background: Coronary heart disease (CHD) is the most common cause of mortality globally, yet mitochondrial genetic mutations associated with CHD development remain incompletely understood. Methods: The subjects from three Chinese families with LHON underwent clinical, genetic, molecular, and biochemical evaluations. Biochemical characterizations included measuring the effects of the15910C > T mutation on tRNA Thr levels, enzymatic activity of electron transport chain complexes, membrane permeability, and the mitochondria-mediated generation of both reactive oxygen species (ROS) and adenosine triphosphate (ATP).
Background
Different Cardiovascular diseases remain the most prominent cause of death globally, with coronary heart disease (CHD) remaining a highly complex and heterogeneous disease the onset of which is typically influenced by a range of environmental and genetic factors, although in some cases single gene mutations can drive disease [1, 2] . While many studies to date have sought to identify nuclear genomic factors linked with CHD incidence, relatively few studies have specifically investigated CHD risk arising as a consequence of mitochondrial mutations [3] [4] [5] . Such investigations are important, as abnormal mitochondrial functionality has been found to be a potential driver of hypertension and other cardiovascular diseases [6, 7] . Multiple previous studies have identified linked between specific mitochondrial DNA (mtDNA) mutations and hypertension, including the tRNA Ile 4295A > G mutation, as well as the tRNA Ile 4263A > G, tRNA Met /tRNA Gln 4401A > G, and tRNA Met 4435A > G mutations which were specifically linked to hypertension in Chinese individuals [8] [9] [10] [11] .
To explore additional mutations linked with CHD pathogenesis, we are conducting ongoing systematic screening efforts assessing mtDNA mutations among Chinese CHD patients. As a part of this effort, we have identified one three-generation family presenting with evidence of CHD transmitted matrilineal, with 6/24 analyzed adults in this family exhibiting CHD of varying severity. When we analyzed their mtDNA, we detected the presence of a tRNA Thr 15910C > T mutation of the M7b'c haplogroup. This mutation occurred in the stem region of this tRNA (conventional position 25) a site that is highly conserved and the mutation of which is predicted to result in structural and functional changes that have the potential to disrupt normal mitochondrial functionality. After identifying this mutation we followed up on its biological significance in cybrid cell lines bearing this mutation, measuring the effects of this15910C > T mutation on tRNA Thr levels, enzymatic activity of electron transport chain complexes, membrane permeability, and the mitochondria-mediated generation of both reactive oxygen species (ROS) and adenosine triphosphate (ATP).
Methods

Subjects
Eighty genetically unrelated Han Chinese subjects with CHD including a three-generation Han Chinese family (Q5) were recruited from affiliated hospital of Qingdao university. In addition, 113 unrelated controls were also obtained from among volunteers in the same area. All participants provided informed consent, and underwent both clinical evaluation and blood sample collection. The Qingdao University ethics committee oversaw and approved this study.
Assessment of risk factors
Relevant risk factors in the present study included hypertension, hyperlipidemia, diabetes, a history of smoking, or a family history of CHD. Patient blood pressure was measured according to standard methods using the average of three readings. Hypertension was designated as a systolic blood pressure ≥ 140 mmHg and/or a diastolic blood pressure ≥ 90 mmHg as per JNC VI criteria. Diabetes was diagnoses in patients based on the presence of either a need for antidiabetic medications, or fasting blood glucose > 126 g/dL, as in previous reports.Any individuals who reported having used cigarettes within the past 12 months were designated smokers.
Mitochondrial mutational assessment
The Puregene DNA Isolation Kits (Biomega) was used to isolate total genomic DNA from study participants, after which mitochondrial genomic DNA was assessed via Southern blotting as in previous research. A total of 24 overlapping PCR fragments were generated and amplified in order to provide full coverage of the mitochondrial genome, using appropriate pairs of light/heavy strand primers used in previous studies. An ABI 3700 automated DNA sequencer was then employed to sequence each of these fragments following purification with a Big Dye Terminator Cycle sequencing reaction kit. The consensus revised Cambridge sequence (Gen-Bank accession number: NC_012920) was then used for alignment of these sequenced fragments. Detection of the 15910C > T mutation in family members, 80 unrelated CHD patients, and other controls was performed as in previous studies.
Cell culture
The Epstein-Barr virus was used to generate immortalized patient cell lines from the proband patient (III-3) bearing the 15910C > T mutation, as well as from a control individual (C2). These cells were cultured in RPMI 1640 containing 10% FBS. Cybrid cells were generated by adapting previous protocols. Briefly, bromodeoxyuridine (BrdU)-resistant 143B.TK − cells were cultured in DMEM containing 5% FBS, and the ρ o 206 cell line lacking mtDNA derived from these same cells was also grown under these conditions in the presence of 50 μg uridine/ml. The patient and control cell lines were then enucleated and fused with the ρ o 206 cells. The resultant cybrid cell lines were then selected in uridine-free DMEM supplemented with BrdU, allowing for donorderived cybrid lines that could then be assessed for the m.15910C > T mutation, amounts of mtDNA, and other cellular genetic features. The resultant cybrid lines were maintained in DMEM containing 5% FBS.
Northern blotting
TRIzol was used to isolate total mitochondrial RNA from knockdown or control cell lines, as in previous studies [12] . In brief, two micrograms of total mitochondrial RNA were electrophoresed through a 10% polyacrylamide/7 M urea gel in Tris-borate-Ethylenediaminetetraacetic acid (EDTA) buffer (TBE) (after heating the sample at 65°C for 10 min), and then electroblotted onto a positively charged nylon membrane for the hybridization. Analysis with oligodeoxynucleotide probes. In total, we followed by transfer onto a positively charged membrane which was then combined with appropriate DIG oligodeoxynucleoside probes based on previously described approaches, using tRNA Thr , tRNA His , tRNA Ala , and tRNA Glu utilized in previous studies [3, 12] .
Western blotting
Western blotting was used to assess protein levels in cells, via first electrophoretically separating 20 μg of protein from each sample via SDS-PAGE. These samples were then transferred onto PVDF membranes, which were then probed with primary antibodies against ND4, ND1, ND6, CYTB, ATP6, CO2, and VDAC. Secondary Affini Pure goat anti-mouse IgG and goat anti-rabbit IgG conjugated to peroxidase enzymes were then used to probe these blots, followed by use of an ECL system for chemiluminescent detection. Densitometric band quantification was then performed as in previous studies [9, 10] .
Measurements of enzymatic activity
The complex I, II, III, and IV activities were assessed as in previous studies [12] . In brief, Citrate synthase activity was analyzed by the reduction of DTNB at 412 nm in the assay buffer. Complex I activity was determined by following the decrease in the absorbance due to the NADH oxidation at 340 nm in assay buffer. The activity of complex II was analyzed by tracking the secondary reduction of 2,6-dichlorophenolindophenol by decylubiquinone (DB) at 600 nm in the assay buffer. Complex III activity was determined by measuring the reduction of cytochrome c at 550 nm with reduced decylubiquinone in the assay buffer. Complex IV activity was measured by monitoring the oxidation of reduced cytochrome c as a decrease of absorbance at 550 nm. Complex I-IV activities were normalized by citrate synthase activity [3, 12] .
Measuring ATP levels
In order to assess ATP generation in cells, the Cell Titer-Glo Luminescent Cell Viability Assay kit (Promega) was used based on provided protocols [12] . In brief, after a 30 min equilibration of the cell plate to room temperature, 100 μl of the assay reagent was added into each well with 20,000 cells and the content was mixed for 2 min on an orbital shaker to induce cell lysis. After 10 min incubation in room temperature, the luminescence was read on a microplate reader [12] . 
Mitochondrial membrane potential measurements
The JC-10 Assay Kit (Abcam) was used to measure mitochondrial membrane potential based on provided protocols as detailed elsewhere [3, 12] . In brief, cells were plated onto 96-well cell culture plate overnight in growth medium. In the first plated cell, JC-10 dyeloading solution was added for 30 min at 37°C, 5% CO 2 . Alternatively, the second plated cells were preincubated with 10 μM of the FCCP for 30 min at 37°C, 5% CO 2 prior to staining with JC-10 dye. Samples were measured at Ex/Em = 490/530 and 490/590 nm with a microplate reader [3, 12] .
Assessment of ROS levels
The MitoSOX Red Mitochondrial Superoxide Indicator (Invitrogen, M36008) was used to assess ROS production in live cells based on provided protocols as described previously [3, 12] . In brief, approximately 2 × 10 6 cells of each cell line were harvested, resuspended in PBS, supplemented with 100 μM of MitoSOX and 2% FBS. After incubation at 37°C for 20 min. Finally, cells were resuspended. Samples were analyzed by the flow cytometer system, with an excitation at 488 nm and emission at 529 nm. 10,000 events were analyzed in each sample [3, 12] .
Statistical analysis
Unpaired, two-tailed Student's t-tests were used to compare all values in this study. SPSS v17.0 and GraphPad Prism v 6.0 were used for all analysis, and p < 0.05 was the significance threshold.
Results
Clinical presentation
The proband (Q5-III-3) was first diagnosed with CHD upon presenting at the Cardiology Clinic of affiliated hospital of Qingdao university, after which he underwent a full medical evaluation. The patient was diagnosed with hypertension (159/99 mmHg), significant ischemia (65% narrowing was evident upon coronary angiography), and high cholesterol (LDL-C = 159 mg/dL, TC = 232 mg/dL). The patient was not affected by any other comorbid conditions such as diabetes or neurological disease. When family members of this patients were evaluated for these same conditions, 5 were diagnosed with all three of these conditions ( Fig. 1a and Table 1 ). In each case, any fathers with CHD had not transmitted it to their children, whereas mothers did transmit it, suggesting matrilineal inheritance consistent with mitochondrial involvement in this inherited CHD risk. 
Analysis of mitochondrial mutations
To explore potential mitochondrial mutations linked with inherited CHD risk, we sequenced the mitochondrial genome of this proband patient Q5-III-3. A total of 45 mutations were evident in their mitochondrial genome upon comparison with the revised Cambridge consensus sequence (NC_012920), and the mitochondrial haplogroup for this patient was identified to be M7b'c ( Fig. 2) . As shown in Table 2 , of these 45 variants, 19 were known silent variants, 14 were known D-loop variants, 8 were known missense mutations affecting protein-coding genes, 2 were known 12S rRNA variants, 1 was a known 16 s rRNA variant, and one was a novel homoplasmy 15910C > T mutation in the tRNA Thr gene (Fig. 1b) . The detected missense mutations were as follows: 5460G > A (Ala331Thr) in the ND2 gene, 7853G > A (Val90Ile) in the CO2 gene, the 8701A > G (Thr59Ala) in the ATP6 gene, the 10398A > G (Thr114Ala) in the ND3 gene, 12,811 T > C (Tyr159His) in the ND5 gene, the 14766C > T (Thr > Ile), 14978A > G (Ile78Val), and m.15326A > G (Thr > Ala) in the CYTB gene. We compared the variance at these mutated RNA residues phylogenetically across 16 different primate species, revealing this tRNA Thr 15910C > T mutation to have a 100% conservation index across species, making it more likely to have functional significance when mutated as in this patient. Moreover, this mutation was also not detected when other 79 unrelated patients and 113 Chinese control subjects were analyzed.
Mutation leads to decreased mitochondrial tRNA Thr levels
We next assessed how this 15910C > T mutation altered the metabolism of tRNA Thr , subjecting cybrid cell lines bearing this mitochondrial mutation to Northern blotting using probes specific to this and 3 other tRNAs. We found that tRNA Thr levels in these mutant cybrid lines were significantly reduced relative to control wild type cells (Fig. 2) , with baseline tRNA Thr levels in these mutant cells being 65.25% of those in control cells, with 5S RNA used for normalization purposes. In contrast, baseline tRNA His , tRNA Ala , and tRNA Glu levels in these mutant cell lines were unchanged relative to control cells (102.13, 98.89, and 107.91%, respectively).
Mutation leads to reduced mitochondrial protein levels
We next performed Western blotting to assess levels of the mtDNA-encoded components of the respiratory complex in cells bearing the 15910C > T mutation or controls. As shown in Fig. 3 , e found that mutant cells expressed mitochondrial protein levels that were 19.31 to 31.55% of those in control cells (average was 24.96%; P < 0.05). These mutated cells also showed clear 
Mutation led to decreased complex I and III activity
We further assessed the consequences of this m.15910C > T mutation on oxidative phosphorylation using isolated mitochondrial from our mutant and control cybrid cell lines. We found that complex I and III activity in the 15910C > T mutant mitochondria was 66.72, and 75.48% that of the activity observed in control cells, whereas no changes in complex II/IV activity were observed (Fig. 4a) .
Mutation leads to reduced mitochondrial ATP generation
We further assessed the generation of ATP by wild type and mutant cells in an effort to better gauge how this mutation influenced oxidative phosphorylation. To test this, either glycolysis or oxidative phosphorylation were selectively induced in cells via culture with glucose, glucose + oligomycin, or 2deoxy-D-glucose + pyruvate. When cells could only engage in oxidative phosphorylation, mutant cells bearing the 15910C > T mutation,exhibited ATP production that was 65.68-67.98% (average: 67.37%) of that in control cells (Fig. 4b) .
Mutation leads to increased ROS production
We next assessed ROS production in our mutant cybrid cell lines via flow cytometry, comparing baseline staining intensity for each cell line to that upon oxidative stress in order to obtain a ratio corresponding to ROS generation. We observed somewhat increased ROS generation for our mutant cybrid cell lines bearing the 15910C > T mutation, with ROS production 118.45-123.98%, (average: 121.04%) that of control cells (Fig. 4c ).
Discussion
Mitochondrial DNA mutations have been associated with CHD in precious studies [13] [14] [15] . In this study, we offer evidence of a novel mitochondrial mutation which is linked to an elevated risk of CHD. This mutation was detected among adult matrilineally-related individuals in a three-generation Chinese family, with affected individuals presenting with CHD, hypertension and hyperlipidemia. This CHD risk was matrilineally inherited, and a mutational analysis revealed the presence of a 15910C > T mutation at the C25 position in the tRNA Thr sequence -a residue which is normally highly conserved and which is predicted to be important for tRNA stability(- Fig. 1c ). This mutations is predicted to destabilize the Fig. 3 Western blot analysis of mitochondrial proteins. a Twenty micrograms of total cellular proteins from various cell lines were electrophoresed through a denaturing polyacrylamide gel, electroblotted and hybridized with respiratory complex subunits in mutant and control cells with VDAC as a loading control. b Quantification of 6 respiratory complex subunits. The levels of ND6, ND4, ATP6, CYTB, CO2 and ND1 in three mutant cybrid cell lines and control cybrid cell lines were determined. The error bars indicate two standard errors of the means. p indicates the significance, according to the t-test, of the differences between mutant and control cell lines base-pairing at this site (25C-10G), potentially altering the secondary structure of this tRNA, as has previously been reported for the tRNA Ile 4300A > G and tRNA-Leu(UUR) 3273 T > C mutations [16, 17] . When cybrid cells bearing this mutation were generated, their baseline tRNA Thr levels were reduced by 37.5% relative to healthy control cells, suggesting that there may be a resultant destabilization of this mutated tRNA Thr resulting in its more rapid degradation, as previously described previously such as the 3243A > G mutation of tRNA Leu(UUR) [18] [19] [20] [21] . As the mitochondrial dysfunction stemming from the 15910C > T mutation was relatively mild, this suggests that this mutation alone is unlikely to cause CHD. As shown in Additional file 1: Table S1 , we observed a~24.96% reduction in mitochondrial protein levels in cells bearing this mutation, and these cells als exhibited altered complex I/III activity which may coincide with increased electron leakage and In the present study, the reduced levels of mitochondrial proteins (an average decrease of~29%) were comparable with the reduced rate of mitochondrial protein synthesis observed in cell lines bearing the hypertension-associated m.4435A > G, m.4401A > G and m.4263A > G mutations [9] [10] [11] . Indeed, consistent with this we found that ROS production was elevated in cybrids expressing this 15910C > T mutation. Such ROS production can lead to significant damage to cellular macromolecules including DNA and proteins, potentially leading to cellular dysfunction or apoptotic cell death which, if it were to occur in cardiac muscle cells, could contribute to the observed CHD phenotype, potnetially explaining how these mutations contribute to the observed matrilineal CHD, as hypertension-associated mitochondrial tRNA Ala m.5655A > G m.5587 T > C, tRNA Leu(CUN) m.12280A > G and tRNA Met m.4467 C > A detailed previously [22] [23] [24] .
As the 15910C > T mutation was homoplasmic in nature in the study subjects, this suggests that the mutation is relatively mild, consistent with the limited changes in mitochondrial functionality observed herein. Even so, our study suggests that this gene mutation is linked to an elevated risk of CHD development, with the ultimate odds of CHD development likely depending on a combination of environmental, lifestyle, and nuclear genetic factors in concert with the observed mitochondrial dysfunction. Indeed, other mutations in nuclear genes may also contribute to mitochondrial dysfunction in patients bearing the 15910C > T mutation, potentially resulting in the observed CHD phenotype. Moreover, the nuclear genetic or epigenetic factors may contribute to the development of clinical phenotype in subjects carrying the 15910C > T mutation.
The study has several limitations. Firstly, this investigation is limited by relatively low number of patients included because the subjects only obtained from one hospital. Secondly, the homoplasmic form, mild mitochondrial dysfunction, late onset, and incomplete penetrance of CHD observed in this Chinese family carrying the 15910C > T mutation suggest that the mutation is an inherited risk factor necessary for the development of CHD but may by itself be insufficient to produce a clinical phenotype. Finally, the tissue-specific effect of this 15910C > T mutation may be attributed to the tissuespecific RNA metabolism or the involvement of nuclear modifier genes.
Conclusions
Our results suggest that the mitochondrial tRNA Thr 15910C > T mutation is linked to CHD incidence. This mutation leads to altered metabolism of this particular tRNA, thus resulting in abnormal mitochondrial functionality and enhanced ROS production. Other nuclear genetic mutations may also act in concert with the 15910C > T mutation to amplify consequent mitochondrial dysfunction in affected patients, and extended ROS production in cardiovascular cells may be linked to CHD onset. Our results thus suggest a potential new mechanism liked to the underlying pathology of CHD, indicating future avenues for therapeutic research.
